In the case of ALS, two key RNA processing events involving the stathmin 2 (STMN2) (Baughn et al., 2023) and UNC13A genes (Brown et al., 2022, Ma et al., 2022, Lipstein, 2022) are targets for therapeutic interventions. This evidence concerns the gene STMN2 and amyotrophic lateral sclerosis.